Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EGFR mutation in gefitinib-responsive small-cell lung cancer.

Literature DB >> 16357019

EGFR mutation in gefitinib-responsive small-cell lung cancer.

I Okamoto, J Araki, R Suto, M Shimada, K Nakagawa, M Fukuoka.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2005 PMID： 16357019 DOI： 10.1093/annonc/mdj114

Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976

Keyword Cloud
Cited

× No keyword cloud information.

32 in total

1. A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors.

Authors: Yong Zhang; Ling Ye; Huijun Zhang; Xuehua Chen; Haiying Ji; Gang Chen; Lu Zhang; Tengfei Zhang; Meiling Jin
Journal: J Thorac Dis Date: 2018-10 Impact factor: 2.895

Review 2. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors: Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal: Lancet Oncol Date: 2015-04 Impact factor: 41.316

Review 3. Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration.

Authors: Alessandro Tuzi; Elena Bolzacchini; Matteo B Suter; Alice Giaquinto; Antonio Passaro; Stefania Gobba; Ilaria Vallini; Graziella Pinotti
Journal: J Thorac Dis Date: 2017-05 Impact factor: 2.895

4. Detecting EGFR alterations in clinical specimens-pitfalls and necessities.

Authors: Sofi Isaksson; Pär-Ola Bendahl; Annette Salomonsson; Mats Jönsson; Monica Haglund; Alexander Gaber; Karin Jirström; Per Jönsson; Ake Borg; Leif Johansson; Johan Staaf; Maria Planck
Journal: Virchows Arch Date: 2013-10-26 Impact factor: 4.064

5. Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.

Authors: Hongyang Lu; Bo Chen; Jing Qin; Fajun Xie; Na Han; Zhiyu Huang
Journal: Oncol Lett Date: 2018-02-13 Impact factor: 2.967

6. Targeted therapies in small cell lung cancer.

Authors: Hong-Yang Lu; Xiao-Jia Wang; Wei-Min Mao
Journal: Oncol Lett Date: 2012-07-06 Impact factor: 2.967

7. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.

Authors: Jennifer J Wheler; Apostolia M Tsimberidou; Gerald S Falchook; Ralph G Zinner; David S Hong; Jansina Y Fok; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Razelle Kurzrock
Journal: Mol Cancer Ther Date: 2013-08-20 Impact factor: 6.261

Review 8. Genetic changes in small cell lung carcinoma.

Authors: Edurne Arriola; Israel Cañadas; Montse Arumí; Federico Rojo; Ana Rovira; Joan Albanell
Journal: Clin Transl Oncol Date: 2008-04 Impact factor: 3.405

9. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors: Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal: J Thorac Oncol Date: 2013-07 Impact factor: 15.609

10. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.